24 June 2021

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report

2021-06-24T12:23:55-07:00

*April 2021* Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report2021-06-24T12:23:55-07:00
24 June 2021

EGFR-Mutated Metastatic NSCLC: Evolving Practice Standards and Opportunities for Improving Outcomes

2021-06-24T12:14:42-07:00

This is a great resource for newly-diagnosed EGFR lung cancer patients to learn from experts in this field about the

EGFR-Mutated Metastatic NSCLC: Evolving Practice Standards and Opportunities for Improving Outcomes2021-06-24T12:14:42-07:00
21 June 2021

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC

2021-06-21T13:44:55-07:00

*May 2021* The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC2021-06-21T13:44:55-07:00
21 June 2021

Ask the Experts: Progression. Now What? Necessary Testing, Common Mechanisms of EGFR-Dependent Resistance, and Possible Treatment Strategies

2021-06-21T13:19:15-07:00

*June 2021* This webinar focuses on necessary testing, common mechanisms of EGFR-dependent resistance, and possible treatment strategies. Dr. Josh Bauml

Ask the Experts: Progression. Now What? Necessary Testing, Common Mechanisms of EGFR-Dependent Resistance, and Possible Treatment Strategies2021-06-21T13:19:15-07:00
Go to Top